MDPPP
MDPPP (3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone) is a pyrrolidine synthetic cathinone combining a methylenedioxy ring with a pyrrolidine core. Sold as a research chemical since the 2000s, it is a dopamine reuptake inhibitor. Human data is minimal and all effect information is anecdotal.
01 Overview
MDPPP is one of the earlier pyrrolidinophenone cathinones, marketed as a legal-grey stimulant. The short propiophenone chain makes it relatively less potent than MDPV, but it retains the compulsive character of the pyrrolidine class.
Pyrrolidine cathinones like MDPPP are especially prone to compulsive redosing, alongside cardiovascular strain, comedown and unknown neurotoxicity. No controlled human studies exist; figures are approximate.
02 Mechanism
Noradrenaline-dopamine reuptake inhibitor at the dopamine and noradrenaline transporters, with the methylenedioxy group adding modest serotonergic character.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 15–35 mg | Insufflated | Strong redose urge. |
| Common | 20–50 mg | Oral | Anecdotal only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| StimulationEnergy and alertness. | Anecdotal | ||
| EuphoriaMild dopaminergic mood lift. | Anecdotal | ||
| Appetite suppressionReduced hunger. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Compulsive redosingStrong compulsion to redose typical of pyrrolidine cathinones. | Severe | Near universal | Anecdotal | |
| Cardiovascular strainRaised heart rate and blood pressure. | Severe | Common | Unconfirmed | |
| ComedownFatigue and low mood after use. | Moderate | Common | Anecdotal |